tiprankstipranks
Trending News
More News >
Adherium Ltd. (AU:ADR)
ASX:ADR
Australian Market
Advertisement

Adherium Ltd. (ADR) AI Stock Analysis

Compare
31 Followers

Top Page

AU:ADR

Adherium Ltd.

(Sydney:ADR)

Rating:47Neutral
Price Target:
Adherium Ltd. is facing substantial financial challenges with declining revenues, negative profitability, and cash flow issues. The technical analysis suggests a bearish trend with the stock trading below key moving averages. Valuation metrics are unfavorable, with a negative P/E ratio and no dividend yield. These factors collectively result in a low overall stock score, indicating potential risks for investors.

Adherium Ltd. (ADR) vs. iShares MSCI Australia ETF (EWA)

Adherium Ltd. Business Overview & Revenue Model

Company DescriptionAdherium Limited develops, manufactures, and supplies digital health technologies that address sub-optimal medication use in chronic diseases in New Zealand, Australia, Europe, North America, and Asia. The company offers Hailie, an asthma and chronic obstructive pulmonary disease medication adherence solution for patients with chronic respiratory diseases. It also provides Bluetooth enabled Hailie sensors, which wrap around a patient's inhalers and offers real-time feedback to patients; Hailie app; and Hailie portal. The company was incorporated in 2001 and is based in Auckland, New Zealand.
How the Company Makes MoneyAdherium Ltd. generates revenue primarily through the sale of its adherence monitoring devices and associated software solutions. The company partners with pharmaceutical companies, healthcare providers, and payers to integrate its technology with existing medication regimens, enhancing treatment efficacy and patient engagement. Revenue streams include direct sales of devices, subscription fees for its software platform, and potential licensing agreements. Significant partnerships with pharmaceutical companies and healthcare organizations amplify its market reach and contribute to its earnings by embedding Adherium's technology into broader healthcare solutions.

Adherium Ltd. Financial Statement Overview

Summary
Adherium Ltd. faces significant financial challenges, with negative profitability and cash flow metrics. Despite a low debt burden, the company struggles with declining revenues, negative margins, and cash flow issues. Without a clear path to improve operational efficiency and revenue growth, financial sustainability remains a concern.
Income Statement
45
Neutral
Adherium Ltd. has experienced declining total revenue over the past few years, with a significant drop from 2023 to 2024. The company has persistently negative net margins, with a net loss for each year observed. Gross profit margins have been negative, indicating cost management issues. Moreover, EBIT and EBITDA margins are also negative, reflecting operational challenges.
Balance Sheet
50
Neutral
The company's debt-to-equity ratio is low, suggesting limited reliance on debt financing, which is a positive aspect. However, stockholders' equity has been decreasing over the years, raising concerns about financial stability. The equity ratio indicates that a significant portion of the company's assets is financed by equity, but the declining total assets and stockholders' equity are concerning.
Cash Flow
40
Negative
Adherium Ltd. has consistently negative free cash flow, with increasing negative operating cash flows year-on-year. The operating cash flow to net income ratio is unfavorable due to persistent losses. Although the company has had some financing inflows, the cash burn from operations and capital expenditures is worrying.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue840.98K3.19M529.00K401.00K2.22M
Gross Profit267.70K1.69M-690.00K-789.00K677.00K
EBITDA-11.56M-9.91M-12.65M-12.74M-8.46M
Net Income-10.22M-9.86M-10.04M-15.04M-11.40M
Balance Sheet
Total Assets9.89M12.68M8.53M17.04M6.72M
Cash, Cash Equivalents and Short-Term Investments6.20M9.08M5.28M15.18M4.58M
Total Debt93.20K44.00K85.00K0.000.00
Total Liabilities3.41M3.47M3.00M3.00M3.33M
Stockholders Equity6.48M9.21M5.54M14.04M3.38M
Cash Flow
Free Cash Flow-10.61M-9.32M-9.89M-11.30M-7.46M
Operating Cash Flow-10.61M-9.28M-9.61M-11.27M-7.32M
Investing Cash Flow-37.00-41.00K-279.00K-29.00K-138.00K
Financing Cash Flow7.73M13.07M0.0021.90M11.34M

Adherium Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.89B-0.33-41.61%2.23%23.26%-2.03%
50
Neutral
AU$15.39M-58.27%-7.20%28.70%
47
Neutral
AU$9.32M-253.69%-2.82%52.38%
46
Neutral
AU$2.86M-218.52%-30.80%-90.53%
€19.27M-513.22%
44
Neutral
AU$11.49M-103.74%14.84%41.19%
38
Underperform
AU$7.47M-191.40%-55.00%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:ADR
Adherium Ltd.
0.01
-0.01
-50.00%
AU:UCM
Uscom Limited
0.01
-0.01
-50.00%
DE:1I4
HeraMED Ltd.
0.02
0.01
100.00%
AU:AT1
Atomo Diagnostics Ltd.
0.02
0.00
0.00%
AU:IRX
InhaleRx Limited
0.04
0.01
33.33%
AU:CBL
Control Bionics Ltd.
0.04
-0.05
-55.56%

Adherium Ltd. Corporate Events

Adherium Issues New Shares, Affirms Regulatory Compliance
Aug 4, 2025

Adherium Limited has issued 66,208,082 fully paid ordinary shares without disclosure to investors under the Corporations Act 2001. The company confirms compliance with relevant provisions of the Act and states there is no excluded information required to be disclosed. This announcement reflects Adherium’s ongoing commitment to maintaining transparency and regulatory compliance, which may impact its market positioning and stakeholder confidence.

Adherium Ltd. Announces Quotation of New Securities on ASX
Aug 4, 2025

Adherium Ltd. announced the quotation of 66,208,082 ordinary fully paid securities on the Australian Securities Exchange (ASX) as part of a previously announced transaction. This move is expected to enhance the company’s financial flexibility and potentially strengthen its market position within the digital health sector, offering potential benefits to stakeholders.

Adherium Limited Announces Proposed Securities Issue to Boost Capital
Aug 4, 2025

Adherium Limited announced a proposed issue of securities, including 70,208,082 ordinary fully paid shares and 70,208,082 options expiring on July 31, 2026, with an exercise price of $0.005. This strategic move is aimed at raising capital, potentially strengthening the company’s financial position and supporting its growth initiatives in the digital health sector.

Adherium Secures A$0.35M to Strengthen Financial Position
Aug 4, 2025

Adherium Limited has successfully secured A$0.35 million through an institutional placement to bolster its financial flexibility and working capital. This capital raise, alongside existing cash reserves and proceeds from a recent entitlement offer, positions Adherium to pursue organic growth opportunities and strengthens its balance sheet, enhancing its ability to execute strategic objectives.

Adherium Addresses Administrative Oversight in ASX Lodgement
Jul 25, 2025

Adherium Limited announced a delay in lodging the Appendix 3H with the ASX due to an administrative oversight, which the company views as an isolated incident. Despite this, Adherium maintains confidence in its compliance practices with ASX Listing Rules, suggesting minimal impact on its operations or stakeholder relations.

Adherium Limited Announces Cessation of Securities
Jul 25, 2025

Adherium Limited announced the cessation of 418,539,981 securities due to the expiry of options without exercise or conversion as of June 30, 2025. This development may impact the company’s capital structure and could influence investor perceptions regarding its financial strategy and market positioning.

Adherium’s Substantial Shareholding Change Enhances Market Position
Jul 22, 2025

Adherium Limited has announced a change in the substantial holding of its shares by Phillip Asset Management Ltd, acting as trustee for BioScience Managers Translation Fund I. The fund increased its voting power from 12.89% to 16.00% through an institutional ANREO take-up and retail shortfall underwriting, impacting 108,791,917 shares. This change signifies a strengthened position for the fund in Adherium, potentially influencing the company’s strategic decisions and market positioning.

Adherium Ltd. Issues Unquoted Equity Securities to Bolster Financial Strategy
Jul 22, 2025

Adherium Ltd. announced the issuance of 223,791,917 unquoted equity securities, which are options expiring on July 31, 2026, with an exercise price of $0.005. This move is part of previously announced transactions and is not intended for quotation on the ASX, potentially impacting the company’s financial strategy and stakeholder interests by expanding its capital base.

Adherium Ltd. Announces Quotation of New Securities on ASX
Jul 22, 2025

Adherium Ltd. has announced the application for quotation of 223,791,917 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of a previously announced transaction, which could potentially strengthen the company’s financial position and market presence, offering new opportunities for growth and engagement with stakeholders.

Adherium Appoints Dawn Bitz as CEO to Drive Global Expansion
Jul 22, 2025

Adherium Limited has appointed Dawn Bitz as Chief Executive Officer, effective immediately. With nearly 30 years of experience in medical technology and digital health, Ms. Bitz is set to lead the company’s expansion of its Hailie® platform in key global markets, emphasizing the US. Her appointment underscores Adherium’s commitment to accelerating the commercial adoption of reimbursed respiratory monitoring solutions, aiming to enhance patient outcomes and expand market reach.

FIL Limited Ceases to be a Substantial Holder in Adherium Ltd.
Jul 21, 2025

Adherium Ltd. has announced that FIL Limited and its associated entities have ceased to be substantial holders in the company as of July 17, 2025. This change in substantial holding involves a reduction in FIL’s voting power to 4.96% with 77,982,072 common stock shares, potentially impacting the company’s shareholder dynamics and market perception.

UBS Group AG Adjusts Stake in Adherium Ltd., Reducing Voting Power
Jul 21, 2025

Adherium Ltd. has announced a change in the interests of its substantial holder, UBS Group AG, which now holds a reduced voting power of 10.69% from the previous 12.13%. This change reflects a shift in UBS’s relevant interests in Adherium’s voting securities, potentially impacting the company’s shareholder dynamics and market perception.

Adherium Ltd. Issues Unquoted Securities to Bolster Financial Strategy
Jul 17, 2025

Adherium Ltd. has announced the issuance of 186,208,082 unquoted securities, which are part of a previously announced transaction. This move is part of the company’s ongoing efforts to manage its equity and financial strategies, potentially impacting its market positioning and stakeholder interests.

Adherium Limited Announces Quotation of New Securities on ASX
Jul 17, 2025

Adherium Limited has announced the quotation of 186,208,082 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of a previously announced transaction, and it is expected to enhance the company’s market presence and liquidity, potentially benefiting stakeholders by increasing the company’s visibility and access to capital markets.

Adherium Completes $1.4 Million Retail Entitlement Offer to Boost Growth
Jul 17, 2025

Adherium Limited has successfully completed the Retail component of its Accelerated Non-Renounceable Entitlement Offer, raising a total of $1.4 million. This funding, combined with the previously raised $3.092 million from the Institutional component, will support the company’s growth strategy, including scaling patient onboarding and enhancing its digital respiratory management solutions. The proceeds will be used for hiring in the US, onboarding customers, recruiting a CEO, and general working capital, positioning Adherium to further its leadership in the digital respiratory health sector.

UBS Group AG Acquires Substantial Stake in Adherium Ltd.
Jul 9, 2025

Adherium Ltd. has announced that UBS Group AG and its related bodies corporate have become a substantial holder in the company as of July 7, 2025. UBS Group AG now holds a 12.13% voting power in Adherium Ltd., with significant shares held through its branches and associates, indicating a notable investment in the company.

Adherium Announces Change in Substantial Holder’s Voting Power
Jul 9, 2025

Adherium Limited has announced a change in the interests of its substantial holder, Trudell Medical Limited. The change occurred due to the dilution of Trudell’s holdings following the issuance of new shares by Adherium. As a result, Trudell’s voting power in Adherium has decreased from 19.90% to 12.89%. This adjustment in voting power may impact Trudell’s influence over Adherium’s corporate decisions, potentially affecting its strategic direction and stakeholder interests.

Adherium Limited Announces Change in Substantial Holder Voting Power
Jul 8, 2025

Adherium Limited has experienced a change in the voting power of a substantial holder, Phillip Asset Management Ltd atf BioScience Managers Translation Fund I, due to the issuance of new shares. This change has resulted in a dilution of their holdings from 19.90% to 12.89%. This adjustment in voting power may impact the influence Phillip Asset Management has within the company, potentially affecting its strategic decisions and stakeholder dynamics.

Adherium Announces Investor Webinar on Retail Entitlement Offer
Jul 8, 2025

Adherium Limited has announced an Investor Webinar to update the market on its Retail Entitlement Offer, which is open to eligible retail shareholders in Australia and New Zealand. The offer began on July 1, 2025, and will close on July 10, 2025. The webinar, scheduled for July 9, 2025, will feature a presentation by Non-Executive Director Kevin Gessner, providing important updates for shareholders and supporters. This initiative is part of Adherium’s ongoing efforts to engage with its stakeholders and provide transparency regarding its financial strategies.

FIL Limited Acquires Substantial Stake in Adherium Limited
Jul 7, 2025

FIL Limited has become a substantial holder in Adherium Limited, acquiring a 5.62% voting power through 77,982,072 common stock shares. This acquisition marks a significant investment by FIL Limited, potentially impacting Adherium’s market position and signaling confidence in the company’s future prospects.

Adherium Limited Announces Cessation of Securities
Jul 7, 2025

Adherium Limited announced the cessation of 1,118,184 stock appreciation rights due to the expiry of options or other convertible securities without exercise or conversion as of June 30, 2025. This cessation may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and future growth potential.

Regal Funds Management Increases Stake in Adherium Ltd.
Jul 7, 2025

Adherium Ltd. has announced a change in the interests of its substantial holders, with Regal Funds Management Pty Limited and its associates increasing their voting power from 22.78% to 26.29%. This change reflects a strategic move by Regal Funds Management to strengthen its position within the company, potentially impacting Adherium’s governance and future strategic decisions.

Adherium Limited Issues Unquoted Securities
Jul 3, 2025

Adherium Limited has announced the issuance of 488,479,082 unquoted securities, specifically options expiring on July 31, 2026. This issuance is part of previously announced transactions and is not intended to be quoted on the ASX, potentially impacting the company’s financial strategy and stakeholder interests.

Adherium Resolves Share Allotment Delay in Entitlement Offer
Jul 3, 2025

Adherium Limited announced the resolution of a delay in the allotment and issue of new shares and options under its Institutional Entitlement Offer, which was caused by a settlement issue with an overseas investor. The allotment is now scheduled for 3 July 2025, with no changes to the remaining timetable of the Entitlement Offer. This development ensures the continuation of the company’s fundraising efforts, potentially impacting its financial stability and market operations.

Adherium Launches $4.492 Million Entitlement Offer
Jul 1, 2025

Adherium Limited has announced the opening of its accelerated non-renounceable entitlement offer to raise approximately $4.492 million. This offer is available to eligible shareholders and is part of the company’s strategy to strengthen its financial position and support future growth. The offer will close on July 10, 2025, with new shares and options expected to begin trading on July 18, 2025.

Adherium Updates Securities Issuance Date for Institutional Investors
Jul 1, 2025

Adherium Limited announced an update regarding the issuance of securities to institutional investors, with the date now set for July 2, 2025. This accelerated non-renounceable entitlement offer aims to strengthen the company’s financial position, potentially enhancing its market presence and operational capabilities.

Adherium Updates Securities Issuance Plan
Jun 26, 2025

Adherium Limited has announced an update to a previous announcement regarding the issuance of securities. The update reflects an amendment to the number of securities to be issued, as detailed in a replacement prospectus lodged on June 26, 2025. This update pertains to an accelerated non-renounceable entitlement offer, commonly known as a JUMBO or ANREO. The announcement signifies a strategic move by Adherium to adjust its financial strategy, potentially impacting its market positioning and stakeholder interests.

Adherium Ltd. Launches A$4.492 Million Entitlement Offer
Jun 26, 2025

Adherium Ltd. has announced an accelerated non-renounceable entitlement offer to raise approximately A$4.492 million. This offer allows eligible shareholders to purchase new shares and options, with the potential for additional bonus options if exercised by November 2025. The offer is partially underwritten and aims to enhance the company’s capital structure. The increased subscription amount reflects strong support from stakeholders, indicating potential positive impacts on Adherium’s market positioning and operational capabilities.

Adherium Closes $4.492 Million Institutional Entitlement Offer Amid Strong Demand
Jun 26, 2025

Adherium Limited has successfully closed the institutional component of its Accelerated Non-Renounceable Entitlement Offer, raising $4.492 million due to strong demand. The company is poised to enhance its market penetration in the U.S. healthcare sector, leveraging its smart inhaler technology to improve patient care and reduce costs. With commercial agreements in place and plans to expand its patient base, Adherium is set to capitalize on its innovative solutions in respiratory health.

Adherium Ltd. Announces Change in Substantial Holder Interests
Jun 25, 2025

Adherium Ltd. has announced a change in the interests of its substantial holder, Regal Funds Management Pty Limited and its associates. The change reflects an adjustment in the voting power and control over a significant number of ordinary shares, impacting the company’s shareholder structure and potentially influencing future corporate decisions.

Adherium Limited Announces Accelerated Securities Offer
Jun 24, 2025

Adherium Limited has announced a proposed issue of securities through an accelerated non-renounceable entitlement offer. This initiative involves issuing up to 800 million unlisted options over shares, exercisable at $0.005, with expiration dates in 2026. The offer aims to strengthen the company’s capital base and support its strategic growth initiatives, potentially impacting its market positioning and stakeholder interests.

Adherium Ltd. Launches A$4 Million Entitlement Offer
Jun 24, 2025

Adherium Ltd. has announced a non-renounceable accelerated pro-rata entitlement offer to raise approximately A$4 million. This initiative aims to strengthen the company’s financial position and support its ongoing operations. The offer includes new shares and options for eligible shareholders, with PAC Partners Securities partially underwriting the offer. This capital raising effort is expected to bolster Adherium’s market positioning and provide additional resources for its strategic initiatives.

Adherium Launches $4 Million Entitlement Offer to Expand U.S. Operations
Jun 24, 2025

Adherium Limited is launching a partially underwritten accelerated non-renounceable entitlement offer to raise up to $4 million. The funds will be used to expand operations in the U.S., including hiring employees and contractors, recruiting a CEO, and general working capital. The initiative has received strong backing from major shareholders and venture capital funds, indicating confidence in Adherium’s growth strategy and its potential impact on the respiratory care market.

K One W One Limited Acquires Substantial Stake in Adherium Ltd.
Jun 23, 2025

Adherium Limited has announced that K One W One Limited has become a substantial holder in the company, acquiring 66,836,248 ordinary shares, which represents a 7.44% voting power. This development indicates a significant investment and interest in Adherium, potentially impacting its market position and signaling confidence from investors in the company’s future prospects.

Adherium Ltd. Announces Change in Substantial Holder’s Voting Power
Jun 23, 2025

Adherium Ltd. has experienced a change in the interests of a substantial holder, Trudell Medical Limited, which has impacted the voting power associated with Adherium’s ordinary shares. This change in interest, including a share consolidation and entitlement offer, has adjusted Trudell Medical Limited’s voting power from 22.15% to 19.90%, reflecting a strategic shift in their investment position within Adherium.

Adherium Ltd. Sees Increase in Substantial Holder’s Voting Power
Jun 23, 2025

Adherium Ltd. has experienced a change in the interests of a substantial holder, Phillip Asset Management Ltd atf BioScience Managers Translation Fund I. The fund increased its voting power in Adherium Ltd. from 16.32% to 19.90% through the voluntary conversion of convertible notes into ordinary shares, impacting the company’s shareholder structure.

Adherium Limited Announces Quotation of New Securities on ASX
Jun 23, 2025

Adherium Limited has announced the application for quotation of 140,293,872 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its market presence and operational capacity, potentially impacting its industry positioning and offering new opportunities for stakeholders.

Adherium Issues Stock Appreciation Rights to Employees
May 28, 2025

Adherium Limited announced the issuance of 2,000,000 stock appreciation rights under an employee incentive scheme. These unquoted securities are subject to transfer restrictions and are not listed on the ASX until the restrictions are lifted, reflecting the company’s strategy to incentivize and retain key personnel.

Adherium Limited Announces Director’s Acquisition of Convertible Notes
May 22, 2025

Adherium Limited announced a change in the director’s interest, with George Baran acquiring 1,200,000 convertible notes. This acquisition follows shareholder approval and reflects ongoing strategic financial maneuvers within the company, potentially impacting its market positioning and stakeholder interests.

Adherium Ltd. Issues 2.2 Million Convertible Notes
May 20, 2025

Adherium Ltd. announced the issuance of 2,225,000 convertible notes, which are unquoted equity securities. This move is part of the company’s financial strategy to enhance its capital structure, potentially impacting its market position by providing additional resources for growth and development in the digital health sector.

Adherium Limited Announces Convertible Notes Issuance
May 19, 2025

Adherium Limited has announced a proposed issuance of 900,000 convertible notes, scheduled for November 10, 2025. This move is part of a strategic effort to raise capital, potentially impacting the company’s financial structure and market positioning, and offering new opportunities for stakeholders.

Adherium Secures $900,000 to Boost U.S. Expansion of Smartinhaler Platform
May 19, 2025

Adherium Limited has announced a successful capital raise of $900,000 through the issuance of convertible notes, supported by Phillip Asset Management Limited and Trudell Medical Limited. The funds will be used to further the roll-out of the Hailie® Smartinhaler® platform in the U.S. and for general working capital, potentially strengthening Adherium’s market position in digital health solutions for respiratory care.

Adherium Ltd. Appoints New Director with Significant Stock Interest
May 8, 2025

Adherium Ltd. has announced the appointment of Keven Gessner as a director, effective May 8, 2025. As part of his role, Gessner holds 2,000,000 Stock Appreciation Rights, indicating a significant interest in the company’s future performance. This appointment is a strategic move that could influence Adherium’s market positioning and operational strategies, potentially impacting stakeholders positively by aligning leadership with shareholder interests.

Adherium Limited Announces Director Change
May 8, 2025

Adherium Limited has announced that William Hunter has ceased to be a director of the company as of May 8, 2025. The notice details Hunter’s interests in the company’s securities, which include 174,170 fully paid ordinary shares. This change in directorship may impact the company’s governance and strategic direction, but specific implications for stakeholders or the company’s operations are not detailed in the announcement.

Adherium Strengthens Leadership Team to Boost US Market Expansion
May 8, 2025

Adherium Limited has announced key leadership appointments to bolster its strategic marketing and sales efforts for the Hailie® Smartinhaler® platform in the US. The appointments include Keven Gessner as Non-Executive Director, Jason Hochman as Head of US Commercial/GTM, and David Haddad as Head of Product. These strategic hires aim to enhance Adherium’s market presence and accelerate its commercial growth in the US healthcare market, leveraging their extensive experience in digital health and respiratory care. The company’s recent capital raise of $2.6 million further supports its commitment to expanding its operations and driving the adoption of its technology.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 08, 2025